MA54903A - Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 - Google Patents
Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1Info
- Publication number
- MA54903A MA54903A MA054903A MA54903A MA54903A MA 54903 A MA54903 A MA 54903A MA 054903 A MA054903 A MA 054903A MA 54903 A MA54903 A MA 54903A MA 54903 A MA54903 A MA 54903A
- Authority
- MA
- Morocco
- Prior art keywords
- il18r1
- kits
- compositions
- methods
- inflammatory disease
- Prior art date
Links
- 101000961065 Homo sapiens Interleukin-18 receptor 1 Proteins 0.000 title 1
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962802828P | 2019-02-08 | 2019-02-08 | |
US201962815223P | 2019-03-07 | 2019-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54903A true MA54903A (fr) | 2021-12-15 |
Family
ID=71947518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054903A MA54903A (fr) | 2019-02-08 | 2020-02-07 | Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220056106A1 (fr) |
EP (1) | EP3920953A4 (fr) |
JP (1) | JP2022519819A (fr) |
KR (1) | KR20210130168A (fr) |
CN (1) | CN113645991A (fr) |
AU (1) | AU2020217793A1 (fr) |
BR (1) | BR112021015222A2 (fr) |
CA (1) | CA3127962A1 (fr) |
IL (1) | IL285344A (fr) |
MA (1) | MA54903A (fr) |
MX (1) | MX2021009247A (fr) |
WO (1) | WO2020163715A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202043234A (zh) | 2019-01-24 | 2020-12-01 | 美商普羅米修斯生物科學股份有限公司 | Gpr35調節劑 |
WO2024030278A1 (fr) * | 2022-08-05 | 2024-02-08 | Illumina, Inc. | Méthodes mises en œuvre par ordinateur d'identification de variants rares qui provoquent des niveaux élevés d'expression génique |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776731A (en) * | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
JP5595632B2 (ja) * | 2004-07-16 | 2014-09-24 | 敦生 関山 | Il−18レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物 |
EP3430172A4 (fr) * | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | Méthode de diagnostic d'une maladie inflammatoire chronique de l'intestin par l'intermédiaire de rnase t2 |
-
2020
- 2020-02-07 WO PCT/US2020/017212 patent/WO2020163715A1/fr unknown
- 2020-02-07 KR KR1020217028586A patent/KR20210130168A/ko unknown
- 2020-02-07 MA MA054903A patent/MA54903A/fr unknown
- 2020-02-07 EP EP20752095.8A patent/EP3920953A4/fr active Pending
- 2020-02-07 BR BR112021015222A patent/BR112021015222A2/pt unknown
- 2020-02-07 AU AU2020217793A patent/AU2020217793A1/en active Pending
- 2020-02-07 CN CN202080027427.4A patent/CN113645991A/zh active Pending
- 2020-02-07 MX MX2021009247A patent/MX2021009247A/es unknown
- 2020-02-07 CA CA3127962A patent/CA3127962A1/fr active Pending
- 2020-02-07 JP JP2021543124A patent/JP2022519819A/ja active Pending
-
2021
- 2021-08-03 IL IL285344A patent/IL285344A/en unknown
- 2021-08-06 US US17/396,581 patent/US20220056106A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021015222A2 (pt) | 2021-12-28 |
KR20210130168A (ko) | 2021-10-29 |
US20220056106A1 (en) | 2022-02-24 |
CA3127962A1 (fr) | 2020-08-13 |
MX2021009247A (es) | 2021-09-08 |
WO2020163715A1 (fr) | 2020-08-13 |
EP3920953A1 (fr) | 2021-12-15 |
AU2020217793A1 (en) | 2021-09-30 |
IL285344A (en) | 2021-09-30 |
JP2022519819A (ja) | 2022-03-25 |
EP3920953A4 (fr) | 2022-12-14 |
CN113645991A (zh) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK4015003T3 (da) | Forbedret antistof-oligonukleotid-konjugat | |
MA56212A (fr) | Compositions et méthodes de traitement du cancer | |
EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
DK3684930T3 (da) | Modificering af ikke-kodende plante-RNA-molekylers specificitet for inaktivering af genekspression | |
MA50269A (fr) | Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon | |
EA201592223A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA52208A (fr) | Biomarqueurs pour une maladie du greffon contre l'hôte | |
MA43347B1 (fr) | Compositions et méthodes permettant d'inhiber l'expression du gène de lpa | |
MX2021005224A (es) | Composiciones y metodos para inhibir la expresion del gen de hidroxiacido-oxidasa 1 (glicolato-oxidasa) (hao1). | |
PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
EA202092086A1 (ru) | Ингибиторы аргиназы | |
EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
MX2016012123A (es) | Composiciones para modular la expresion de ataxina 2. | |
EA201492123A1 (ru) | Композиции и способы для модулирования экспрессии семейства генов smn | |
EA201390214A1 (ru) | Гетероарилы и их применение | |
EA201592225A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201071057A1 (ru) | Производные азетидина и циклобутана как ингибиторы jak-киназ | |
MA31564B1 (fr) | Inhibition par arni de l'expression du canal alpha-enac | |
EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
EA201070127A1 (ru) | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
EA201592157A1 (ru) | Низкомолекулярные ингибиторы фиброза | |
MA54903A (fr) | Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 | |
EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения |